Addition of 25-hydroxyvitamin D levels to the Deyo-Charlson Comorbidity Index improves 90-day mortality prediction in critically ill patients by unknown
RESEARCH Open Access
Addition of 25-hydroxyvitamin D levels to
the Deyo-Charlson Comorbidity Index
improves 90-day mortality prediction in
critically ill patients
Bisundev Mahato1,2,3, Tiffany M. N. Otero1,4, Carrie A. Holland5, Patrick T. Giguere1, Ednan K. Bajwa5,7,
Carlos A. Camargo Jr.6,7,8 and Sadeq A. Quraishi1,9*
Abstract
Background: The Deyo-Charlson Comorbidity Index (DCCI) has low predictive value in the intensive care unit (ICU).
Our goal was to determine whether addition of 25-hydroxyvitamin D (25OHD) levels to the DCCI improved 90-day
mortality prediction in critically ill patients.
Methods: Plasma 25OHD levels, DCCI, and Acute Physiology and Chronic Health Evaluation II (APACHE II) scores
were assessed within 24 h of admission in 310 ICU patients. Receiver operating characteristic curves of the
prediction scores, without and with the addition of 25OHD levels, for 90-day mortality were constructed and the
areas under the curve (AUC) were compared for equality.
Results: Mean (standard deviation) plasma 25OHD levels, DCCI, and APACHE II score were 19 (SD 8) ng/mL, 4 (SD 3),
and 17 (SD 9), respectively. Overall 90-day mortality was 19 %. AUC for DCCI vs. DCCI + 25OHD was 0.68 (95 % CI
0.58–0.77) vs. 0.75 (95 % CI 0.67–0.83); p < 0.001. AUC for APACHE II vs. APACHE II + 25OHD was 0.81 (95 % CI
0.73–0.88) vs. 0.82 (95 % CI 0.75–0.89); p < 0.001. There was a significant difference between the AUC for DCCI + 25OHD
and APACHE II + 25OHD (p = 0.04) but not between the AUC for DCCI + 25OHD and APACHE II (p = 0.12).
Conclusions: In our cohort of ICU patients, the addition of 25OHD levels to the DCCI improved 90-day mortality
prediction compared to the DCCI alone. Moreover, the predictive capability of DCCI + 25OHD was comparable to that
of APACHE II. Future prospective studies are needed to validate our findings and to determine whether the use of
DCCI + 25OHD can influence clinical decision-making.
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Background
Mortality prediction scores are widely used in the inten-
sive care unit (ICU) to predict the likelihood of survival
from critical illness. These scores often assist healthcare
providers in their discussions with patients and their fam-
ily members about realistic expectations regarding ICU
care and may be helpful in setting more patient-centered
goals, assessing resource utilization, and providing higher
quality of care [1]. Mortality prediction scores are also
widely used by researchers to risk adjust for severity of
illness, especially in multivariable regression models [2, 3].
While several mortality prediction scores for critical
illness have been developed and are in current use, the
Acute Physiology and Chronic Health Evaluation II
(APACHE II), first published in 1985 [4], is the most
commonly used worldwide [5]. However, APACHE II
score calculations require measurement of specific
physiological parameters within 24 h of ICU admis-
sion—this can be challenging, especially if a robust elec-
tronic medical record system is not available. Moreover,
given that the score is heavily based on post-admission
physiological assessments, it is not readily available at
the time of admission, and it is of limited value for
decision-making at the outset of critical illness.
Given the challenges of the APACHE II calculation
(and for other similar mortality prediction models heav-
ily influenced by physiologic assessments), the use of
scoring systems based largely on medical history (i.e., co-
morbidities), despite being less accurate, are growing in
popularity in the ICU literature [6, 7]. Among these, the
Deyo-Charlson Comorbidity Index (DCCI) has been re-
ported most frequently in studies of critical illness [8].
The DCCI [9], although modified from the original
Charlson Index [6], continues to have a low predictive
value for mortality in ICU patient cohorts [10–14]. Vari-
ous modifications of either the original Charlson Index
or DCCI have been made to improve their predictive
values. These modifications have typically involved the
use of administrative data [15–18], and they are not
specific to ICU patients. And although the inclusion
of several laboratory test results in the APACHE II
scoring method is integral to its superior performance
over the DCCI for mortality prediction in ICU pa-
tients [19], the impact of adding easily measurable or
readily available biomarkers to improve the predictive
capabilities of the DCCI in ICU patients has been
largely underexplored [20].
Mounting evidence suggests that vitamin D status is
associated with mortality in critically ill patients [21–27].
Indeed, assessment of vitamin D status in ICU patients is
becoming increasingly common in the USA and world-
wide [21, 28, 29]. In general, serum 25-hydroxyvitamin D
(25OHD) levels are considered the best marker of total
body vitamin D status [30]. Therefore, our goal was to
determine whether the addition of 25OHD levels, mea-
sured at the outset of critical illness, to the DCCI im-
proves mortality prediction in ICU patients.
Methods
We performed a retrospective analysis of the data from an
ongoing prospective cohort study designed to assess vita-
min D status in critically ill patients. A subset of these pa-
tients was previously described in studies that investigated
the association of vitamin D status with duration of mech-
anical ventilation and 90-day mortality in ICU patients
[25, 31]. For the present study, subjects were recruited
from three, 18-bed ICUs (1 surgical, 1 medical, and 1
mixed surgical/medical) at the Massachusetts General
Hospital (MGH), in Boston, MA. The ICUs received ad-
missions from all surgical and medical services except for
Cardiac Surgery and Cardiology, respectively. All subjects
were enrolled between 06/01/2012 and 05/30/2015. MGH
is a 1052-bed, teaching hospital and a level-one trauma
center, which serves a diverse population in and around
Eastern Massachusetts. The Partners Human Research
Committee (Institutional Review Board) approved the
study protocol.
Inclusion and exclusion criteria
All adult males and females, ≥18 years of age, and
who were expected to require at least 48 h of critical
care (as determined by the treating ICU team) were
deemed eligible to participate. Informed consent was
obtained either directly from subjects or appropriate
healthcare surrogates. Subjects were only included in the
study if blood samples to assess vitamin D status could be
obtained within 24 h of admission to the ICU. Exclusion
criteria included a known history of anemia at the time of
ICU admission (defined as hematocrit <25 %), pregnancy
or immediate post-partum status, and history of vitamin
D supplementation ≥4000 IU/day. To minimize con-
founding from either partially treated, new-onset illness,
or chronic illnesses, subjects were also excluded if they
were transferred from another ICU or had been in an ICU
within 1 year of the most current admission. Patients
expected to transition to “comfort only measures”
were also excluded.
Blood sample processing and biomarker assays
Following informed consent, fresh blood was acquired
from an indwelling arterial or central venous catheter
and was collected directly into an EDTA-containing tube
(lavender top). The sample was immediately stored on
ice and then centrifuged within 30 min to separate out
plasma. All samples were centrifuged at 2300 rpm for
15 min at a temperature of 4 °C. The separated plasma
was immediately transferred to polypropylene tubes and
stored at −80 °C until biomarker testing was ready to be
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initiated. Assays were performed at the Harvard Medical
School Clinical and Translational Science Award core la-
boratory at MGH. Plasma 25OHD (combined D2 and D3)
levels were measured by enzyme-linked immunoabsorbent
assay, using commercially available kits (Abbott Labora-
tories, Abbott Park, IL). Intra- and inter-assay coefficients
of variation were both <10 %.
Clinical data collection
The MGH electronic medical records system used ab-
stract baseline demographic information, including (1)
age, (2) sex, (3) race, (4) body mass index (BMI), and (5)
type of patient (surgical vs. medical). To obtain in-
hospital mortality data within 90-days of ICU admission,
individual electronic medical records were reviewed. For
patients discharged alive from the hospital and who con-
tinued to receive care within the Partners Healthcare
network (which includes MGH and its affiliates), individ-
ual electronic outpatient medical records were reviewed
to document all-cause mortality within 90 days of ICU
admission. All individual records were cross-referenced
with the Social Security Death Index Master File to
finalize 90-day mortality cases.
Statistical analysis
Descriptive statistics were tabulated for the analytic co-
hort. Continuous data were reported as means with
standard deviations (SDs), and categorical values were
expressed as proportions. To graphically represent the
relationship between 25OHD levels and DCCI as well as
APACHE II, we constructed locally weighted scatterplot
smoothing (LOWESS) curves. LOWESS is a type of
nonparametric regression, which summarizes a relation-
ship between two variables in a fashion that initially re-
lies on limited assumptions about the form or strength
of the relationship [32]. The rationale and methods
underlying the use of LOWESS for depicting the local
relationship between measurements of interest across
parts of their ranges have previously been described
[33]. To investigate the association of 25OHD levels with
90-day mortality, we performed logistic regression ana-
lyses while controlling for biologically plausible covaria-
tes—as such, we developed two main models: the first
controlled for (1) age, (2) sex, (3) race, (4) BMI, (5) type
of patient, and (6) DCCI, while the second controlled for
(1) age, (2) sex, (3) race, (4) BMI, (5) type of patient, and
(6) APACHE II score.
Receiver operating characteristic (ROC) curves were
constructed to assess the areas under the curve (AUC)
for the ability of each predictive model to correctly iden-
tify survivors vs. non-survivors. An AUC of 0.5 suggests
no predictive value, 0.7–0.8 suggests good predictive
value, and >0.8 suggests excellent predictive value. Four
different models were tested for their ability to predict 90-
day mortality in the analytic cohort, namely (1) DCCI, (2)
DCCI + 25OHD, (3) APACHE II, and (4) APACHE II +
25OHD. 25OHD levels were categorized into nationally
accepted threshold levels of <10 ng/mL, 10–19.9 ng/mL,
20–29.9 ng/mL, and ≥30 ng/mL. Recent evidence suggests
that these thresholds may be relevant and applicable to
hospitalized and critically ill patients as well [34–36]. We
assigned all plausible serial permutations of the sub-score
values of the DCCI and APACHE II (0–6) to each 25OHD
category in order to derive the highest AUC value. Serial
number scores were assigned since the existing literature
suggests that there is a near inverse linear association be-
tween 25OHD levels and adverse outcomes in hospitalized
patients [34–36]. The final AUC values were compared
for equality using the methodology described elsewhere
[37]. Moreover, optimal cut-points were determined from
the ROC curves by identifying scores that provided the
highest cumulative value for sensitivity and specificity.
In a previous study [25], our group demonstrated that
100 ICU patients provided sufficient power to detect a
meaningful association between admission 25OHD level
as well as APACHE II score and 90-day mortality. There-
fore, we assumed that the current analytic cohort size
(n = 310) would be adequately powered to undertake
the study objectives. All analyses were performed in
STATA 13.0 (StataCorp LP, College Station, TX). A
two-tailed p < 0.05, and any 95 % confidence interval
not spanning 1, was considered statistically significant
for all analyses.
Results
Three hundred and ten patients comprised the analytic
cohort. All blood samples were obtained within 24 h of
ICU admission, with 72 % of samples being obtained
within 6 h of admission to the ICU. The general charac-
teristics of the study cohort, stratified by 90-day survi-
vors vs. non-survivors, are shown in Table 1. LOWESS
curve analysis demonstrated a near inverse relationship
between DCCI as well as APACHE II and 25OHD levels
between 0 and 10 ng/mL (Fig. 1). Between 25OHD levels
of 10 and 30 ng/mL, there was significant flattening of
the curve. Multivariable logistic regression analyses in-
cluding either DCCI or APACHE II score as a covariate
demonstrated an inverse association between 25OHD
levels and 90-day mortality in both models (OR 0.84;
95 % CI 0.79–0.91 and OR 0.86; 95 % CI 0.80–0.93, per
1 ng/mL, respectively). DCCI was independently associ-
ated with 90-day mortality (OR 1.32; 95 % CI 1.12–1.57),
as was APACHE II (OR 1.14; 95 % CI 1.08–1.21).
Initial score assignment for 25OHD thresholds was 0
for levels ≥30 ng/mL (since this is widely regarded as a
“normal” level), 1 for levels 20–29.9 ng/mL, 2 for levels
10–19.9 ng/mL, and 3 for levels <10 ng/mL. The re-
spective threshold scores were added to each DCCI and
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APACHE II score and ROC curves were generated to as-
sess the AUCs (Fig. 2). Alternative score assignments did
not result in either a statistically different, clinically
meaningful, or biologically plausible difference in the
calculated AUCs for DCCI + 25OHD or APACHE II +
25OHD. Moreover, based on the observed relationship
between 25OHD and DCCI as well as APACHE II on
LOWESS curve analysis, we also generated models
where 25OHD levels ≥30 ng/mL designated a score of 0,
levels 10–29.9 ng/mL were designated a score of 1, and
levels <10 ng/mL were designated a score of 3. Again,
this alternative scoring designation did not materially
change any previously obtained results. As such, for the
final models, the initial scoring assignment was retained.
AUC for 25OHD alone was 0.75 (95 % CI 0.67–0.83).
On the other hand, AUC for DCCI alone was 0.68 (95 %
CI 0.59–0.77), and improved to 0.75 (95 % CI 0.66–0.83)
with the addition of 25OHD threshold scores (X2 = 19.1,
p < 0.001). AUC for APACHE II alone was 0.81 (95 % CI
0.73–0.88) and increased slightly to 0.82 (95 % CI 0.75–
0.89) with the addition of 25OHD threshold scores
(X2 = 11.4, p < 0.001). There was no difference be-
tween the AUC for 25OHD alone vs. DCCI + 25OHD
(X2 = 0, p = 0.97). And while there was a significant
difference between the AUC for DCCI + 25OHD vs.
APACHE II + 25OHD (X2 = 4.4, p = 0.04), there was
no difference in the AUC for DCCI + 25OHD vs.
APACHE II alone (X2 = 2.38, p = 0.12).
The optimal cutoff value for 25OHD alone was ≥3
(i.e., <10 ng/mL), with a sensitivity of 45 %, specificity of
91 %, and accuracy of 68 %, while the optimal cutoff
value for DCCI alone was ≥4, with a sensitivity of 63 %,
specificity of 63 %, and accuracy of 63 %. On the other
hand, the optimal cutoff value for DCCI + 25OHD was
≥5, with a sensitivity of 84 %, specificity of 55 %, and ac-
curacy of 70 %. The optimal cutoff value for APACHE II
was ≥12, with a sensitivity of 95 %, specificity of 42 %,
Table 1 General characteristics of the study cohort (n = 310)













BMI (kg/m2) 28 ± 7 30 ± 8 0.08
Type of patient (%) <0.001
Surgical 76 43
Medical 24 57
25OHD (ng/mL) 20 ± 14 12 ± 7 <0.001








DCCI 3 ± 2 5 ± 3 <0.001
Continuous data were reported as means with standard deviations (SDs),
medians with interquartile ranges (IQRs), and categorical values were
expressed as proportions. Body mass index = BMI, Acute Physiology and
Chronic Health Evaluation II = APACHE II; Deyo-Charlson Comorbidity
Index = DCCI; intensive care unit = ICU
P-values in italics represent statistically significant results
Fig. 1 Locally weighted scatterplot smoothing (LOWESS) curve analysis of the relationship between vitamin D status and severity of illness scores.
DCCI = Deyo-Charlson Comorbidity Index; 25OHD = 25-hydroxyvitamin D; APACHE II = Acute Physiology and Chronic Health Evaluation II. LOWESS
curve analysis demonstrates a steep, near inverse, relationship between DCCI (a) as well as APACHE II (b) and 25OHD levels from 0 to 10 ng/mL.
Beyond 25OHD levels of 10, there is progressive flattening of the curve
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and accuracy of 69 %, while the optimal cutoff value for
APACHE II + 25OHD was ≥15, with a sensitivity of
92 %, specificity of 54 %, and accuracy of 73 %.
Discussion
In this retrospective, cohort study, we investigated
whether the addition of 25OHD levels to the DCCI at
initiation of care improved 90-day mortality prediction
(vs. the DCCI alone) in ICU patients and we compared
these findings to the gold standard of APACHE II assess-
ments. We demonstrated that the addition of 25OHD
levels significantly improved the AUC for the DCCI, but
did not materially affect the predictive capability of the
APACHE II. Moreover, our results suggest that the DCCI
+ 25OHD model may perform as well as the APACHE II
alone for predicting 90-day mortality in ICU patients.
However, given the retrospective nature of our study, the
real-time utility of DCCI + 25OHD over the APACHE II
requires further investigation.
Previous studies have reported AUCs for the APACHE
II method, which demonstrates excellent discrimination
between survivors and non-survivors of critical illness
(AUC >0.80) [4, 38, 39]. AUC for the APACHE II ROC
in our study is consistent with what has been reported
in the existing literature. Despite its clinically acceptable
predictive value, APACHE II score calculations can be
cumbersome if an appropriate infrastructure is not in
place. Although most commercially available electronic
medical record (EMR) systems automatically calculate
the APACHE II score, these products may be cost-
prohibitive, especially for smaller healthcare entities [40].
And without a robust EMR, APACHE II calculations
must be performed manually by healthcare providers,
which can be time consuming and therefore prone to
low compliance. Furthermore, APACHE II scores may
provide prognostic information too late after ICU admis-
sion. Since patients need to be admitted to the ICU for
at least 24 h before a score can be calculated, the APA-
CHE II does not help with critical decision-making for
patients and families at the outset of critical illness. In-
deed, many patients and families struggle with decisions
to prolong medical therapy and/or undergo potentially
painful as well as invasive procedures on admission to
the ICU. As such, simple and timely predictive models
for ICU-related mortality have the potential to assist
clinicians in delivering more patient-centered, higher
quality, and cost-effective care.
In 1987, Charlson et al. developed a weighted index,
which took into account both the number and severity
of various comorbid diseases; the purpose of the index
was to develop a 10-year mortality prediction tool for
the general population [6]. In its original form, the
Charlson Comorbidity Index relied on patient interviews
or chart review to classify comorbid diseases. Later,
Deyo et al. adapted it to accommodate the use of the
International Classification of Disease, 9th Edition,
Fig. 2 Receiver operating characteristic (ROC) curves and area under the curves (AUCs). DCCI = Deyo-Charlson Comorbidity Index; 25OHD = 25-
hydroxyvitamin D; APACHE II = Acute Physiology and Chronic Health Evaluation II. a DCCI vs. DCCI + 25OHD (p < 0.001). b APACHE II vs. APACHE
II + 25OHD (p < 0.001). c APACHE II + 25OHD vs. DCCI + 25OHD (p = 0.12). d APACHE II vs. DCCI + 25OHD (p = 0.04)
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Clinical Modification (ICD-9-CM) to calculate the DCCI
from administrative databases [9]. Other modifications
to the original Charlson Comorbidity Index have included
the use of alternate lists of specific diagnoses for comor-
bidities [15], re-assigning comorbidity weights [16, 17],
and updating to the ICD-10-CM codes from ICD-9-CM
codes [16, 18]. Recently, an increasing number of publica-
tions in acute care medicine have used the DCCI to risk-
adjust for severity of illness [34–36, 41, 42]—indeed,
mounting evidence suggests that the DCCI may have ex-
cellent in-hospital, 30-day, and 1-year mortality prediction
in hospitalized patients [43]. Regarding the ICU, DCCI
alone appears to have low predictive value (which is also
observed in the present study) [41], but in combination
with administrative data that reflect acute physiological
processes (e.g., admission diagnosis, need for mechanical
ventilation, initiation of renal replacement therapy), the
AUC of the modified DCCI may be equivalent to the
APACHE II [44]. While such adjustments are helpful for
research purposes, they do not apply to real-time
decision-making at the outset of critical illness. The use of
non-administrative data, such as readily available or easily
measured biomarkers, in conjunction with the DCCI has
been reported to improve mortality prediction in dialysis-
dependent renal failure patients [20] but until now has
largely remained unexplored in the ICU.
Our study suggests that using easily obtained bio-
marker data, more specifically 25OHD levels at initiation
of care, may significantly improve the predictive value of
the DCCI for 90-day mortality in ICU patients, poten-
tially making it a feasible alternative to the APACHE II
score, especially when the necessary acute physiologic
assessments are not readily available. Indeed, several
studies suggest that 25OHD levels at initiation of critical
care are inversely associated with mortality [25, 29, 45].
While vitamin D has traditionally been thought to play a
vital role in bone [46], cardiac [47, 48], and muscle
health [49], primarily by maintaining calcium balance,
recent data support a more pleiotropic effect of vitamin
D on general health [46]. With regards to critical illness,
vitamin D plays a major role in maintaining immune
heath. Recent studies have demonstrated that cells of the
innate and adaptive immune system express the vitamin
D receptor. Low 25OHD levels are associated with de-
pressed macrophage phagocytosis, attenuated chemotaxis,
and proinflammatory cytokine production [50]. Macro-
phages activated through the vitamin D receptor by 1,25-
dihydroxyvitamin D (the most hormonally active vitamin
D metabolite) upregulate expression of cathelicidin [51].
Cathelicidins are endogenous antimicrobial peptides that
are active against a broad spectrum of infectious agents,
such as bacteria, viruses, fungi, and mycobacteria [52].
Moreover, cathelicidins are highly expressed by epithelial
cells at natural barrier sites (e.g., skin, lungs, gut) and
may represent an important first line of defense for
the innate immune system [53]. In addition, vitamin
D is important for the interferon-γ-dependent T cell
responses to infection [54] and therefore may play an
important role in preventing immunoparalysis [55]. And
finally, in animal models, vitamin D supplementation has
been shown to improve coagulation variables and inhibit
endotoxemia [56–58].
It is important to note that at present, it is not stand-
ard practice in most institutions worldwide to routinely
obtain 25OHD levels in ICU patients. Traditionally, this
has been due to a lack of evidence suggesting that as-
sessment of vitamin D status might be helpful in critic-
ally ill patients; however, recent evidence supports the
notion that 25OHD may be an important biomarker in
this patient cohort [30, 35, 36]. Other major barriers to
readily assessing vitamin D status in hospitalized patients
worldwide have been the lack of in-house laboratory
equipment, batched processing protocols, and the cost of
the 25OHD assays themselves. Given the intricacies of ac-
curately measuring steroid hormone levels, many facilities
outsource such measurements, and as such, results may
take several days to be finalized. Similarly, if the overall
volume of testing is insufficient, many facilities process
samples at dedicated time intervals—which may present a
delay in obtaining results for bedside clinical decision-
making. Led by the US National Institute of Standards
and Technology and the National Institutes of Health, a
global Vitamin D Standardization Program (VDSP) has
been launched to assist facilities in ensuring the quality of
their in-house assays and results [59–62]. Moreover, the
recent availability of various point-of-care (POC) vitamin
D testing devices has now made it feasible to obtain
25OHD levels to allow for real-time, bedside clinical
decision-making [63–65]. These devices require very small
amounts of blood (some are similar in design to POC glu-
cose testing units for diabetics), are very affordable, and
provide results within 10 min.
Although we present intriguing evidence regarding the
addition of 25OHD and the DCCI to significantly im-
prove mortality prediction in ICU patients, it is import-
ant to be mindful of potential limitations of our work.
Retrospective cohort studies such as this cannot estab-
lish causation, but it can highlight the existence or ab-
sence of associations and thereby direct future research.
Furthermore, observational studies may be limited by
the lack of a randomly distributed exposure. And despite
adjustment for the multiple potential confounders within
the DCCI and APACHE II, there may still be residual
confounding that contributes to the observed differences
in survival. More specifically, vitamin D status may simply
be a reflection of the overall health of patients, for which
we may be unable to fully adjust. We were also unable to
adjust for immobilization, lack of sun exposure, and
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vitamin D supplementation over the study period. In
addition, 25OHD was only assessed within 24 h of ICU
admission and may not completely represent vitamin D
status at the outset of critical illness (since 25OHD levels
may be influenced by inflammatory responses, fluid load-
ing, and renal wasting of albumin as well as vitamin D
binding protein) [30]. Moreover, changes in vitamin D sta-
tus over the course of the study period were not assessed.
The results of our study also may not be generalizable,
since patients from only one institution and from only
surgical or medical ICUs were included in the analysis
(i.e., excluded patients from the neurosciences, cardiac,
and burn ICUs). We also had a limited sample size (n =
310), which may further impact the generalizability of our
findings. Despite these limitations, the biological plausibility
of vitamin D status as a determinant of survival after critical
illness is undeniable. Interestingly, 25OHD levels alone had
a higher AUC than the DCCI; however, it is unlikely that
clinicians would be willing to make key decisions based on
a single biomarker and ignore the potential impact of
chronic illness on critical care outcomes. Fortunately, the
addition of vitamin D status to the DCCI maintains the ob-
served AUC of 25OHD alone and allows for a prediction
model that is as accurate as APACHE II alone. As such, the
results of our study warrant further investigation to confirm
these findings in larger datasets and to conduct future pro-
spective studies.
Conclusions
We confirm previous studies, which have suggested that
total 25OHD levels upon ICU admission are inversely
associated with the risk of mortality in the post-acute
care setting. In addition, we present novel data that
25OHD levels on admission to the ICU may significantly
improve the predictive value of the DCCI for 90-day
mortality in critically ill patients. This may be particu-
larly helpful in making clinical decisions at initiation of
care in the ICU or in settings where prediction scores
heavily based on physiologic assessments may not be
readily available. Further prospective studies are needed
to validate our findings and to determine whether opti-
mizing vitamin D status in surgical ICU patients may
confer survival benefit from critical illness.
Availability of supporting data
Our Institutional Review Board proposal for this study
specifically states that data will not be shared with any
party outside of the Partners Healthcare Network; our
database will not be available.
Competing interests
SAQ has received consulting fees from Lungpacer, Inc. and Trevena, Inc. In
addition to this, SAQ serves as an uncompensated Board member for both
the Vitamin D Council and the C. Diff Foundation.
Authors’ contributions
BM and SAQ contributed to the concept and design of the manuscript.
TMNO and CAH contributed to the acquisition and interpretation of the
data. BM, TMNO, and SAQ drafted the manuscript. TMNO, PTG, EKB, and CAC
Jr. revised the manuscript. All authors agree to be fully accountable for





TMNO received support from the National Center for Advancing
Translational Sciences, National Institutes of Health, Award Number
TL1TR001062.
CAC received support from the National Institutes of Health grants R01
AI093723 and U01 AI087881. SAQ received support from the National
Institutes of Health grants T32 GM007592, UL1 RR025758, L30 GM102903,
and L30 TR001257.
Author details
1Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts
General Hospital, 55 Fruit Street, GRJ 402, Boston, MA, USA. 2Harvard Medical
School, Boston MA, USA. 3Department of Anesthesiology & Perioperative
Care, University of California – Irvine, Orange CA, USA. 4Tufts University
School of Medicine, Boston, MA, USA. 5Department of Medicine,
Massachusetts General Hospital, Boston, MA, USA. 6Department of
Emergency Medicine, Massachusetts General Hospital, Boston, MA, USA.
7Department of Medicine, Harvard Medical School, Boston, MA, USA.
8Department of Epidemiology, Harvard School of Public Health, Boston, MA,
USA. 9Department of Anaesthesia, Harvard Medical School, Boston MA, USA.
Received: 21 March 2016 Accepted: 15 June 2016
References
1. Zimmerman JE, Wagner DP, Knaus WA, Williams JF, Kolakowski D,
Draper EA. The use of risk predictions to identify candidates for
intermediate care units. Implications for intensive care utilization and cost.
Chest. 1995;108(2):490–9.
2. Kollef MH, Schuster DP. Predicting intensive care unit outcome with scoring
systems. Underlying concepts and principles. Crit. Care Clin. 1994;10(1):1–18.
3. Knaus WA, Wagner DP, Zimmerman JE, Draper EA. Variations in mortality and
length of stay in intensive care units. Ann Intern Med. 1993;118(10):753–61.
4. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of
disease classification system. Crit Care Med Oct. 1985;13(10):818–29.
5. Vincent JL, Moreno R. Clinical review: scoring systems in the critically ill.
Crit Care. 2010;14(2):207.
6. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying
prognostic comorbidity in longitudinal studies: development and validation.
J Chronic Dis. 1987;40(5):373–83.
7. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use
with administrative data. Med Care. 1998;36(1):8–27.
8. Sharabiani MT, Aylin P, Bottle A. Systematic review of comorbidity indices
for administrative data. Med Care. 2012;50(12):1109–18.
9. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use
with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–9.
10. Cleves MA, Sanchez N, Draheim M. Evaluation of two competing methods
for calculating Charlson’s comorbidity index when analyzing short-term
mortality using administrative data. J Clin Epidemiol. 1997;50(8):903–8.
11. Stukenborg GJ, Wagner DP, Connors Jr AF. Comparison of the performance
of two comorbidity measures, with and without information from prior
hospitalizations. Med Care. 2001;39(7):727–39.
12. Holman CD, Preen DB, Baynham NJ, Finn JC, Semmens JB. A multipurpose
comorbidity scoring system performed better than the Charlson index. J
Clin Epidemiol. 2005;58(10):1006–14.
13. Li P, Kim MM, Doshi JA. Comparison of the performance of the CMS
Hierarchical Condition Category (CMS-HCC) risk adjuster with the Charlson
and Elixhauser comorbidity measures in predicting mortality. BMC Health
Serv Res. 2010;10:245.
Mahato et al. Journal of Intensive Care  (2016) 4:40 Page 7 of 9
14. Chu YT, Ng YY, Wu SC. Comparison of different comorbidity measures for
use with administrative data in predicting short- and long-term mortality.
BMC Health Serv Res. 2010;10:140.
15. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use
with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol.
1993;46(10):1075–9. discussion 1081–1090.
16. Halfon P, Eggli Y, van Melle G, Chevalier J, Wasserfallen JB, Burnand B.
Measuring potentially avoidable hospital readmissions. J Clin Epidemiol.
2002;55(6):573–87.
17. Schneeweiss S, Wang PS, Avorn J, Glynn RJ. Improved comorbidity
adjustment for predicting mortality in Medicare populations. Health Serv
Res Aug. 2003;38(4):1103–20.
18. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders
LD, Beck CA, Feasby TE, Ghali WA. Coding algorithms for defining
comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;
43(11):1130–9.
19. Poses RM, McClish DK, Smith WR, Bekes C, Scott WE. Prediction of
survival of critically ill patients by admission comorbidity. J Clin Epidemiol.
1996;49(7):743–7.
20. Fadem SZ. Charlson Comorbidity Scoring System: estimating prognosis for
dialysis patients. http://touchcalc.com/calculators/cci_js. Accessed 16 Jun 2015.
21. Venkatram S, Chilimuri S, Adrish M, Salako A, Patel M, Diaz-Fuentes G.
Vitamin D deficiency is associated with mortality in the medical intensive
care unit. Crit Care. 2011;15(6):R292.
22. Braun A, Chang D, Mahadevappa K, Gibbons FK, Liu Y, Giovannucci E,
Christopher KB. Association of low serum 25-hydroxyvitamin D levels and
mortality in the critically ill. Crit Care Med Apr. 2011;39(4):671–7.
23. Arnson Y, Gringauz I, Itzhaky D, Amital H. Vitamin D deficiency is associated
with poor outcomes and increased mortality in severely ill patients. QJM.
2012;105(7):633–9.
24. Amrein K, Quraishi SA, Litonjua AA, Gibbons FK, Pieber TR, Camargo Jr
CA, Giovannucci E, Christopher KB. Evidence for a U-shaped relationship
between prehospital vitamin D status and mortality: a cohort study. J
Clin Endocrinol Metab. 2014;99(4):1461–9.
25. Quraishi SA, Bittner EA, Blum L, McCarthy CM, Bhan I, Camargo Jr CA.
Prospective study of vitamin D status at initiation of care in critically ill surgical
patients and risk of 90-day mortality. Crit Care Med Jun. 2014;42(6):1365–71.
26. Joshi A, Bhadade R, Varthakavi PK, DeSouza R, Bhagwat NM, Chadha MD.
Vitamin D deficiency is associated with increased mortality in critically ill
patients especially in those requiring ventilatory support. Indian J
Endocrinol Metab Jul. 2014;18(4):511–5.
27. Zajic P, Amrein K. Vitamin D deficiency in the ICU: a systematic review.
Minerva Endocrinol. 2014;39(4):275–87.
28. Padhi R, Panda B, Jagati S, Patra SC. Vitamin D status in adult critically ill
patients in Eastern India: an observational retrospective study. Lung India.
2014;31(3):212–6.
29. Braun AB, Gibbons FK, Litonjua AA, Giovannucci E, Christopher KB. Low
serum 25-hydroxyvitamin D at critical care initiation is associated with
increased mortality. Crit Care Med Jan. 2012;40(1):63–72.
30. Quraishi SA, Camargo Jr CA. Vitamin D in acute stress and critical illness.
Curr Opin Clin Nutr Metab Care. 2012;15(6):625–34.
31. Quraishi SA, McCarthy C, Blum L, Cobb JP, Camargo CA, Jr. Plasma 25-
hydroxyvitamin D levels at initiation of care and duration of mechanical
ventilation in critically ill surgical patients. JPEN J. Parenter. Enteral Nutr. 2015.
32. Cleveland WS. Robust locally weighted regression and smoothing scatterplots.
Journal of the American Statistical Association. 1979;74(368):829–36.
33. Cleveland WS, Devlin SJ. Locally weighted regression: an approach to
regression analysis by local fitting. Journal of the American Statistical
Association. 1988;83(403):596–610.
34. Quraishi SA, Litonjua AA, Elias KM, Gibbons FK, Giovannucci E, Camargo
Jr CA, Christopher KB. Association between pre-hospital vitamin D
status and hospital-acquired new-onset delirium. Br J Nutr. 2015;113(11):
1753–60.
35. Quraishi SA, Litonjua AA, Moromizato T, Gibbons FK, Camargo Jr CA,
Giovannucci E, Christopher KB. Association between prehospital vitamin D
status and hospital-acquired Clostridium difficile infections. JPEN J Parenter
Enteral Nutr Jan. 2015;39(1):47–55.
36. Quraishi SA, Litonjua AA, Moromizato T, Gibbons FK, Camargo Jr CA,
Giovannucci E, Christopher KB. Association between prehospital vitamin D
status and hospital-acquired bloodstream infections. Am J Clin Nutr. 2013;
98(4):952–9.
37. Cleves MA. From the help desk: comparing areas under receiver operating
characteristic curves from two or more probit or logit models. The Stata
Journal. 2002;2(3):301–13.
38. Ho KM, Dobb GJ, Knuiman M, Finn J, Lee KY, Webb SA. A comparison of
admission and worst 24-hour Acute Physiology and Chronic Health
Evaluation II scores in predicting hospital mortality: a retrospective cohort
study. Crit Care. 2006;10(1):R4.
39. Capuzzo M, Valpondi V, Sgarbi A, Bortolazzi S, Pavoni V, Gilli G, Candini G,
Gritti G, Alvisi R. Validation of severity scoring systems SAPS II and APACHE II
in a single-center population. Intensive Care Med. 2000;26(12):1779–85.
40. Shen JJ, Ginn GO. Financial position and adoption of electronic health
records: a retrospective longitudinal study. J Health Care Finance Spring.
2012;38(3):61–77.
41. Quach S, Hennessy DA, Faris P, Fong A, Quan H, Doig C. A comparison
between the APACHE II and Charlson Index Score for predicting hospital
mortality in critically ill patients. BMC Health Serv Res. 2009;9:129.
42. Govani SM, Waljee AK, Stidham RW, Higgins PD. Increasing ultraviolet light
exposure is associated with reduced mortality from Clostridium difficile
infection. United European gastroenterology journal. 2015;3(2):208–14.
43. Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, Januel JM,
Sundararajan V. Updating and validating the Charlson comorbidity index
and score for risk adjustment in hospital discharge abstracts using data
from 6 countries. Am J Epidemiol. 2011;173(6):676–82.
44. Christensen S, Johansen MB, Christiansen CF, Jensen R, Lemeshow S.
Comparison of Charlson comorbidity index with SAPS and APACHE
scores for prediction of mortality following intensive care. Clin
Epidemiol. 2011;3:203–11.
45. Moromizato T, Litonjua AA, Braun AB, Gibbons FK, Giovannucci E,
Christopher KB. Association of low serum 25-hydroxyvitamin D levels and
sepsis in the critically ill. Crit Care Med Jan. 2014;42(1):97–107.
46. Amrein K, Venkatesh B. Vitamin D and the critically ill patient. Curr Opin Clin
Nutr Metab Care. 2012;15(2):188–93.
47. Maiya S, Sullivan I, Allgrove J, Yates R, Malone M, Brain C, Archer N, Mok Q,
Daubeney P, Tulloh R, Burch M. Hypocalcaemia and vitamin D deficiency:
an important, but preventable, cause of life-threatening infant heart failure.
Heart. 2008;94(5):581–4.
48. Bouillon R, Carmeliet G, Verlinden L, van Etten E, Verstuyf A, Luderer HF,
Lieben L, Mathieu C, Demay M. Vitamin D and human health: lessons from
vitamin D receptor null mice. Endocr Rev. 2008;29(6):726–76.
49. Bischoff-Ferrari HA, Conzelmann M, Dick W, Theiler R, Stahelin HB. [Effect of
vitamin D on muscle strength and relevance in regard to osteoporosis
prevention]. Z. Rheumatol. 2003;62(6):518–21.
50. Kankova M, Luini W, Pedrazzoni M, Riganti F, Sironi M, Bottazzi B, Mantovani
A, Vecchi A. Impairment of cytokine production in mice fed a vitamin D3-
deficient diet. Immunology. 1991;73(4):466–71.
51. Pinheiro Da Silva F, Machado MC. Antimicrobial peptides: clinical relevance
and therapeutic implications. Peptides. 2012;36(2):308–14.
52. Durr UH, Sudheendra US, Ramamoorthy A. LL-37, the only human member
of the cathelicidin family of antimicrobial peptides. Biochim Biophys Acta.
2006;1758(9):1408–25.
53. Tollin M, Bergman P, Svenberg T, Jornvall H, Gudmundsson GH, Agerberth
B. Antimicrobial peptides in the first line defence of human colon mucosa.
Peptides. 2003;24(4):523–30.
54. Fabri M, Stenger S, Shin DM, Yuk JM, Liu PT, Realegeno S, Lee HM, Krutzik
SR, Schenk M, Sieling PA, Teles R, Montoya D, Iyer SS, Bruns H, Lewinsohn
DM, Hollis BW, Hewison M, Adams JS, Steinmeyer A, Zugel U, Cheng G, Jo
EK, Bloom BR, Modlin RL. Vitamin D is required for IFN-gamma-mediated
antimicrobial activity of human macrophages. Sci Transl Med. 2011;3(104):
104ra102.
55. Quraishi SA, De Pascale G, Needleman JS, Nakazawa H, Kaneki M, Bajwa EK,
Camargo Jr CA, Bhan I. Effect of cholecalciferol supplementation on vitamin
D status and cathelicidin levels in sepsis: a randomized placebo-controlled
trial. Crit Care Med Sep. 2015;43(9):1928–37.
56. Asakura H, Aoshima K, Suga Y, Yamazaki M, Morishita E, Saito M, Miyamoto
K, Nakao S. Beneficial effect of the active form of vitamin D3 against LPS-
induced DIC but not against tissue-factor-induced DIC in rat models.
Thromb Haemost. 2001;85(2):287–90.
57. Moller S, Laigaard F, Olgaard K, Hemmingsen C. Effect of 1,25-dihydroxy-
vitamin D3 in experimental sepsis. Int J Med Sci. 2007;4(4):190–5.
58. Horiuchi H, Nagata I, Komoriya K. Protective effect of vitamin D3 analogues
on endotoxin shock in mice. Agents Actions. 1991;33(3–4):343–8.
Mahato et al. Journal of Intensive Care  (2016) 4:40 Page 8 of 9
59. Vitamin D. Metabolites quality assurance program. 2010. http://www.nist.
gov/mml/csd/vitdqap.cfm. Accessed 30 May 2016.
60. Tai SS, Bedner M, Phinney KW. Development of a candidate reference
measurement procedure for the determination of 25-hydroxyvitamin
D3 and 25-hydroxyvitamin D2 in human serum using isotope-dilution
liquid chromatography-tandem mass spectrometry. Anal Chem.
2010;82(5):1942–8.
61. Stepman HC, Vanderroost A, Van Uytfanghe K, Thienpont LM. Candidate
reference measurement procedures for serum 25-hydroxyvitamin D3 and
25-hydroxyvitamin D2 by using isotope-dilution liquid chromatography-
tandem mass spectrometry. Clin Chem. 2011;57(3):441–8.
62. Stockl D, Sluss PM, Thienpont LM. Specifications for trueness and precision
of a reference measurement system for serum/plasma 25-hydroxyvitamin D
analysis. Clin Chim Acta. 2009;408(1–2):8–13.
63. Lee S, Oncescu V, Mancuso M, Mehta S, Erickson D. A smartphone platform
for the quantification of vitamin D levels. Lab on a chip. 2014;14(8):1437–42.
64. The Fast Pack System 2013. www.qualigeninc.com. Accessed 30 May 2016.
65. Point of Care Diagnostics 2015. http://www.nanospeed.ca/. Accessed 30
May 2016.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Mahato et al. Journal of Intensive Care  (2016) 4:40 Page 9 of 9
